336 related articles for article (PubMed ID: 25408231)
1. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.
Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R
Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252
[TBL] [Abstract][Full Text] [Related]
4. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
5. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
6. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
Wang H; Zhu L; Gao J; Hu Z; Lin B
Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
[TBL] [Abstract][Full Text] [Related]
7. Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer.
Smith G; Ng MT; Shepherd L; Herrington CS; Gourley C; Ferguson MJ; Wolf CR
Br J Cancer; 2012 Oct; 107(8):1327-36. PubMed ID: 22990650
[TBL] [Abstract][Full Text] [Related]
8. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.
Horio M; Kato T; Mii S; Enomoto A; Asai M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M
Cancer Med; 2012 Oct; 1(2):218-29. PubMed ID: 23342271
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.
Ryner L; Guan Y; Firestein R; Xiao Y; Choi Y; Rabe C; Lu S; Fuentes E; Huw LY; Lackner MR; Fu L; Amler LC; Bais C; Wang Y
Clin Cancer Res; 2015 Jul; 21(13):2941-51. PubMed ID: 25838397
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients.
Chiang YC; Chang MC; Chen PJ; Wu MM; Hsieh CY; Cheng WF; Chen CA
Endocr Relat Cancer; 2013 Apr; 20(2):213-27. PubMed ID: 23329649
[TBL] [Abstract][Full Text] [Related]
11. Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
Fekete JT; Ősz Á; Pete I; Nagy GR; Vereczkey I; Győrffy B
Gynecol Oncol; 2020 Mar; 156(3):654-661. PubMed ID: 31973910
[TBL] [Abstract][Full Text] [Related]
12. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
13. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
[TBL] [Abstract][Full Text] [Related]
14. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
15. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
16. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Staaf J; Sundfeldt K; Horvath G
Cytogenet Genome Res; 2009; 125(1):8-18. PubMed ID: 19617691
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy.
Miao Y; Li S; Yan Q; Li B; Feng Y
Oncol Res Treat; 2016; 39(11):712-719. PubMed ID: 27855385
[TBL] [Abstract][Full Text] [Related]
18. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
[TBL] [Abstract][Full Text] [Related]
19. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.
Koti M; Gooding RJ; Nuin P; Haslehurst A; Crane C; Weberpals J; Childs T; Bryson P; Dharsee M; Evans K; Feilotter HE; Park PC; Squire JA
BMC Cancer; 2013 Nov; 13():549. PubMed ID: 24237932
[TBL] [Abstract][Full Text] [Related]
20. Exosomes as mediators of platinum resistance in ovarian cancer.
Crow J; Atay S; Banskota S; Artale B; Schmitt S; Godwin AK
Oncotarget; 2017 Feb; 8(7):11917-11936. PubMed ID: 28060758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
